CAMP4 Therapeutics Corp. (CAMP)
4.26
-0.07
(-1.62%)
USD |
NASDAQ |
Nov 11, 12:20
CAMP4 Therapeutics Net Income (Quarterly) : -28.96M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -28.96M |
| June 30, 2026 | -33.53M |
| March 31, 2026 | -18.33M |
| December 31, 2025 | -40.28M |
| September 30, 2025 | -15.10M |
| June 30, 2025 | -12.59M |
| March 31, 2025 | -12.43M |
| Date | Value |
|---|---|
| December 31, 2024 | -13.28M |
| September 30, 2024 | -13.48M |
| June 30, 2024 | -12.58M |
| March 31, 2024 | -12.45M |
| December 31, 2023 | -12.99M |
| September 30, 2023 | -11.70M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -42.99M |
| Vericel Corp. | 14.16M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.899M |
| Total Expenses (Quarterly) | 30.86M |
| EPS Diluted (Quarterly) | -0.3668 |
| Enterprise Value | 152.92M |
| Gross Profit Margin (Quarterly) | 72.46% |
| Profit Margin (Quarterly) | -1.52K% |
| Earnings Yield | -47.85% |
| Normalized Earnings Yield | -27.99 |